Compare Abbott Laboratories (ABT) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Kinross Gold Corporation — how do they compare? Abbott Laboratories trades at $95.55 (market cap $166.94B), while Kinross Gold Corporation trades at $23.02 (market cap $28.53B). The key difference: Abbott Laboratories is far larger — about 5.9× Kinross Gold Corporation's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | KGC | |
|---|---|---|
Market Cap | $166.94B | $28.53B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $38.06 |
52-Week Low | $82.57 | $15.19 |
Enterprise Value | $193.69B | $27.08B |
Dividend Yield | 2.63% | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Kinross Gold (KGC) trades at $23.87, down 3.4% over 24 hours amid a bearish technical signal. The company demonstrates strong fundamentals with revenue growing from $3.5B in 2022 to $7.05B in 2025 and net income surging to $2.39B. Recent quarters show consistent earnings beats, with Q2 2026 results expected on July 29. Analyst consensus remains bullish with a $35.33 price target representing 48% upside potential.
KGC presents a compelling value opportunity with attractive valuation ratios (P/E 10.52, EV/EBITDA 5.46) and robust profitability (35.99% net margin). Key risks include gold price volatility and rising operational costs. The company's strong cash flow generation and growth projects support long-term upside, though technical indicators suggest near-term consolidation may continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
